Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Vicore Pharma in connection with a directed share issue of approximately SEK 125 million
Mandate

Vinge has advised Vicore Pharma in connection with a directed share issue of approximately SEK 125 million

November 13, 2019 Capital Markets and Public M&A

Vinge has advised Vicore Pharma, a Swedish rare disease company focused on interstitial lung diseases and related indications, in connection with a directed share issue whereby Vicore Pharma will receive approximately SEK 125 million in issue proceeds.

The subscription price was determined to SEK 16 per share through an accelerated book building process. The share issue was directed to a number of Swedish and international institutional investors. The main purpose of the share issue is to finance Vicore Pharma’s development of current and future product candidates. 
Vinge’s team consisted of Jesper Schönbeck, Nils Fredrik Dehlin and Stephanie Stiernstedt.

 

Related

Vinge has represented Inflexion in connection with the acquisition of Mecenat

 Vinge has represented Inflexion in connection with the acquisition of the Mecenat group from IK. The acquisition of Mecenat is the first investment made through Inflexion's new Enterprise Fund VI, and Inflexion's first acquisition in Sweden.
January 14, 2025

Vinge has advised the sellers in connection with the sale of Färskvaruhuset i Göteborg AB

 Färskvaruhuset i Göteborg AB is a Swedish nationwide supplier to the retail sector within meat and poultry as well as charcuterie and delicatessen products. The acquirer was the international food trading company BPI A/S, headquartered in Denmark.
January 13, 2025

Vinge has advised the seller in conjunction with the sale of Lundby Plåt Aktiebolag

 Lundby Plåt Aktiebolag provides services within sheet metal work. The acquirer was the Gothenburg based contracting and construction services company, Göfast Gruppen AB.
January 13, 2025